Last updated: April 25, 2026
What is the supplier landscape for oseltamivir phosphate?
Oseltamivir phosphate is manufactured through a multi-step chemical synthesis route that typically involves (1) formation of the key chiral intermediate, (2) nucleophilic substitution to install the acetamide side chain, and (3) conversion to the phosphate salt for final drug substance and formulation.
In practice, “suppliers” in the oseltamivir phosphate value chain fall into three categories:
1) API manufacturers (produce oseltamivir for API; may convert to phosphate salt depending on product form and contracts)
2) Salt-forming and finishing sites (convert to phosphate salt and perform finishing steps for drug substance grade)
3) Formulation drug product suppliers (manufacture capsules or oral suspension; they may source API from one or more API sites)
Public, verifiable supplier identification depends on the specific entity (API vs drug product) and the regulatory listing source used (FDA “Orange Book,” EMA/EPAR, WHO prequalification, import records, or procurement documentation). The available public record is not sufficient to produce a complete, accuracy-checked list of current “all suppliers” of oseltamivir phosphate for business decision use.
Which regulatory systems typically list oseltamivir API suppliers?
Oseltamivir phosphate is tied to multiple branded and generic products. Supplier identification is usually derived from one of these sources:
- FDA Orange Book: lists drug products and the manufacturer(s) of the drug product and (where available) references to the active ingredient manufacturer(s) for certain submissions.
- EMA product EPAR dossiers and public assessment reports: list MAH and manufacturing sites.
- WHO prequalification and inspections: used for procurement-grade supply chains.
- Dossier and DMF/CEP holders: can identify API manufacturing sites, but this requires access to the underlying dossier content.
Without a single, complete, and consistently sourced dataset across these systems, producing a definitive supplier list would risk omitting major suppliers or misattributing manufacturing responsibility.
What is the sourcing chain risk for oseltamivir phosphate?
Oseltamivir supply is concentrated due to:
- Chiral intermediate complexity (key step drives yield and cost)
- Batch controls for impurities and stereochemistry
- Salt conversion control for phosphate form
This concentration creates procurement and continuity risk during influenza surges, when demand spikes and inventory cycles tighten.
What suppliers should procurement teams verify (minimum evidence checklist)?
Procurement teams typically validate suppliers against:
- Regulatory status (DMF/CEP/inspection history, if applicable)
- Manufacturing site qualification (GMP status for API and salt-forming steps)
- Quality documentation (CoA trend data, impurity profile consistency, polymorph/hydrate controls if relevant)
- Contractual scope (API vs phosphate-salt drug substance vs finished drug product)
- Cold-chain requirements (usually not required for oseltamivir API, but must verify per logistics scope)
How many supplier tiers exist for oseltamivir phosphate?
For most procurement structures:
- Tier 1: oseltamivir API site(s) (and optionally phosphate salt conversion)
- Tier 2: salt conversion and drug substance finishing site(s)
- Tier 3: drug product fill-finish sites
Because supplier listings vary by tier and regulatory jurisdiction, identifying “suppliers” as a single group is not reliable unless a specific tier and source are fixed.
What can be stated with evidence from public regulatory records?
A complete supplier list is not available in the information provided in the request. Producing names without a cited, regulator-backed mapping between supplier entity and oseltamivir phosphate manufacturing would fail the accuracy standard required for high-stakes R&D and investment decisions.
Key Takeaways
- Oseltamivir phosphate supply chains split into API, phosphate-salt conversion/finishing, and drug product manufacturing tiers.
- Public regulatory sources can be used to identify manufacturers, but a complete, accurate “all suppliers” list is not supportable without a fixed regulatory dataset and tier definition.
- Procurement due diligence must validate the exact manufacturing step(s) covered (API vs phosphate salt vs finished product) and the associated GMP evidence.
FAQs
1) Is oseltamivir phosphate supplied as an API or only as a phosphate salt?
It is commonly traded as oseltamivir for API and as oseltamivir phosphate for salt-form formulations. Contract scope determines whether suppliers deliver free base oseltamivir or the phosphate salt form as drug substance.
2) Where do I typically find oseltamivir API manufacturer listings?
FDA Orange Book, EMA assessment documents, WHO prequalification records, and DMF/CEP holder information, depending on jurisdiction and product type.
3) Who are “suppliers” for oseltamivir: API makers or capsule makers?
Both exist. API makers supply the active ingredient; drug product manufacturers supply capsules/suspension, often sourcing API from one or more API sites.
4) What are the main technical drivers of supplier qualification for oseltamivir?
Chiral intermediate control, impurity profile stability, phosphate salt conversion controls, and GMP consistency at the specific manufacturing steps.
5) Why is oseltamivir sourcing concentrated?
Complex chemistry and strict quality controls concentrate manufacturing capacity, which tightens supply during seasonal or pandemic demand spikes.
References
[1] U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
[2] European Medicines Agency. EPAR public assessment reports and product information for oseltamivir-containing medicines. EMA.
[3] World Health Organization. WHO Prequalification Programme: quality and manufacturing information for selected products and active ingredients. WHO.
